Global Tuberculosis Treatment Drugs Market Report 2020-2030
Forecasts & Analysis of Epidemiology by Regions (United States, Europe, Germany, France, Italy, Spain, UK, Japan & Rest of the World), by Regional Markets (North America, Latin America, Middle East & Africa, Asia & Asia Pacific), Plus Analysis of Leading Nations, by Therapies & Leading Companies in the Tuberculosis Treatment Drugs market
Tuberculosis (TB) is a major public health concern worldwide, with an estimated 10.0 million cases of tuberculosis in 2019, a number that has been relatively stable in recent years. It is interesting to see how WHO, and global companies have taken steps to end tuberculosis worldwide. The growing number of prevalence cases of Multi-Drug Resistant TB and cases of new and relapsed TB among the population of developing and under developing countries have.
Not only the development from the treatment point of view, but also the new development diagnostic tests will play an important role in shifting the dynamics of the tuberculosis market. More than 23 companies have formed an alliance with institutions in developing markets to support clinical therapeutic developments.
The Tuberculosis Treatment Drugs Market is growing at the noteworthy CAGR of 5.8% with the estimated market size of $1,080 million in 2020. Globally market is registered to grow at the CAGR of 5.8% from 2019 to 2020. Growing needs of anti-tuberculosis drugs, increase in multi drug resistance TB cases, government initiatives towards TB elimination and the increase in the pipeline drugs as well as the vaccines will drive the growth of the TB market from 2020 to 2030. In addition, increase in funding will further boost up the institutes and the companies for research in the high TB burden countries.
The Tuberculosis Treatment Drugs Market Report explains the findings of the research of the Tuberculosis treatment market developments and growth factors which is driving the market. It notes key findings and makes recommendations for action for the companies who are actively participating and involved in the R&D of the tuberculosis therapies.
• Understand the dynamics of TB market • Epidemiology Forecast and Analysis Globally and Regionally • Market Forecast & Analysis by Regions, By Nations, By Therapies & By Companies • Promising Therapies in the pipeline • Shift from generics to the effective TB therapies • WHO initiatives to end Global TB • Growing demand of effective therapies in developed/ developing countries • High TB Burden countries and funding appropriations • Effective Diagnostic Tests recently launched & under development
Leading Companies in the Tuberculosis Drugs Market: • Johnson & Johnson • Lupin Limited • Macleods Pharmaceuticals Limited • Pfizer • Otsuka Pharmaceuticals
Buy our report today Global Tuberculosis Treatment Drugs Market Research: Forecasts & Analysis of Epidemiology by Regions (United States, Europe, Germany, France, Italy, Spain, UK, Japan & Rest of the World), by Regional Markets (North America, Latin America, Middle East & Africa, Asia & Asia Pacific), Plus Analysis of Leading Nations, by Therapies & Leading Companies. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview
1.1 Global Tuberculosis Treatment Drugs Market Overview
1.1.1 Global Tuberculosis Treatment Drugs Market Overview
1.1.2 Why You Should Read This Report
1.1.3 How This Report Delivers
1.1.4 Key Questions Answered by This Analytical Report
1.1.5 Who is This Report For?
1.1.6 Methodology
1.1.7 Frequently Asked Questions (FAQ)
1.1.8 Associated Visiongain Reports
1.1.9 About Visiongain
2 Tuberculosis (TB) Disease Background
2.1 Disease Definition
2.2 Transmission of TB
2.2.1 Factors that Determine the Probability of M. tuberculosis Transmission
2.2.2 Characteristics of TB patient associated with Infection
2.2.3 Environmental Factors that enhance the probability that M. tuberculosis will Be transmitted
2.3 Patient Subtypes
2.3.1 Latent TB (TB infection)
2.3.2 Active TB (TB disease)
2.3.3 Difference between Latent TB Infection (LTBI) and active TB Disease
2.4 Tuberculosis Symptoms
2.4.1 On the basis of Signs and Symptoms, TB can be further Classified into: -
2.4.2 Drug-Resistant TB (MDR and XDR)
2.4.3 Multidrug-Resistant TB
2.4.4 Extensively Drug-Resistant TB
2.5 Diagnosis
2.5.1 Diagnosis of Latent tuberculosis infection (LTBI)
2.5.2 Diagnosis of Active tuberculosis infection (ATBI)
2.5.3 Guidelines for Diagnosis from the ATS, IDSA, and Control of Disease Prevention & Control (CDC)
2.5.4 Diagnostic Pipeline
2.6 Treatments for Tuberculosis
2.6.1 Anti-Tuberculosis Drugs
2.6.2 Treatment Guidelines
2.6.3 Tuberculosis Vaccine
3 Tuberculosis Epidemiology Forecast 2019-2020
3.1 World Health Organization Estimates for 2018
3.2 The Global Tuberculosis Epidemiology (2019-2030)
3.3 The United States Tuberculosis Epidemiology (2019-2030)
3.4 The Europe Tuberculosis Epidemiology (2019-2030)
Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.